Ethno-epidemiology of HCV, HIV and Overdose associated with Drug Markets and Drug Tourism
与毒品市场和毒品旅游相关的丙型肝炎病毒、艾滋病毒和药物过量的民族流行病学
基本信息
- 批准号:10409999
- 负责人:
- 金额:$ 56.18万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-09-01 至 2023-01-31
- 项目状态:已结题
- 来源:
- 关键词:AgeAntibodiesBehaviorBehavior TherapyBehavioralCOVID testCOVID testingCOVID-19COVID-19 health disparityCOVID-19 testCOVID-19 testingCOVID-19 vaccinationCOVID-19 vaccineCOVID-19 vaccine evaluationCaliforniaCaringCommunitiesCoronavirusCountryCountyCriminal JusticeDataData LinkagesDatabasesElectronic Health RecordEpidemiologyEthnic OriginFundingFutureGeographic stateHIVHIV/HCVHealthHealth InsuranceHealthcare SystemsHepatitis B VaccinationHepatitis C virusHomelessnessHuman immunodeficiency virus testIncidenceInfectionInfrastructureInjecting drug userInterventionInterviewLegalMeasuresMedicalMexicoMisinformationNational Institute of Drug AbuseNatural experimentNeedle-Exchange ProgramsOutcomeOverdoseParentsParticipantPatient Self-ReportPatternPharmaceutical PreparationsPopulationPositioning AttributePrevalencePreventionProfessional counselorProteinsRaceRandomizedReportingResearchRoleSARS-CoV-2 antibodySARS-CoV-2 antigenSARS-CoV-2 infectionSerologySerology testServicesSiteStructureSubgroupSurveysTestingTrainingTransportationTravelVaccinatedVaccinationVaccinesVisitacceptability and feasibilityaddictionantigen testbasebrief interventioncoronavirus diseasedrug marketefficacy trialfallsfollow-uphealth literacyhigh riskimprovedmemberoverdose preventionpandemic preparednessparent grantpeerpre-exposure prophylaxisprogramsprospectiverapid testingsexsubstance abuse treatmenttheoriesuptakevaccine acceptancevaccine accessvaccine evaluationvaccine hesitancyvaccine-induced immunity
项目摘要
This competitive revision aims to increase access and uptake of COVID-19 testing and vaccination
among people who inject drugs (PWID), a population highly vulnerable to COVID-19. The proposed
RADxUP project, LinkUP, will be nested within the San Diego component of our parent grant, La
Frontera, which was funded by NIDA in 04/20. To date, 31% of La Frontera PWID have tested SARS-
CoV-2 antibody+, of whom 65% had not previously been tested for COVID-19. Only 3% had been
vaccinated by 05/2021 and 45% were vaccine hesitant. Our specific aims are: AIM 1. To prospectively
evaluate the prevalence, predictors and barriers to COVID-19 testing among PWID. AIM 2. To
prospectively assess incidence, predictors and barriers to COVID-19 vaccination among PWID. AIM 3.
To adapt and pilot an intervention offered at a mobile syringe services program (SSP) to improve
uptake of COVID-19 testing and vaccination among PWID. AIM 4. To compare COVID testing and
vaccination rates before and after the state introduces a) COVID-19 rapid testing and b) COVID-19
vaccination at the SSP, which represents a natural experiment. AIM 5. To prospectively assess the
impact of COVID-19 testing and vaccination on PWIDs’ behaviors. To meet Aim 1 and 2, we will
conduct interviews with 400 PWID in La Frontera, results which will be available in Fall 2021. Based on
these findings and input from our Community and Scientific Advisory Board (CSAB), we will select and
adapt a brief intervention to improve COVID-19 testing and vaccination uptake among PWID at the
mobile van of our community partner, OnPoint. The LinkUP intervention will then be piloted among a
subgroup of 150 La Frontera PWID who have not received COVID-19 vaccine or testing and will be
implemented by OnPoint peer counsellors, who will also offer on-site rapid COVID-19 antigen testing
and confirmatory PCR and referrals to the closest COVID-19 vaccination center (until vaccine is offered
at OnPoint by the state). We will evaluate COVID-19 vaccine uptake independently through ongoing La
Frontera study visits that will include self-reported interview data, linkage of electronic health records
with the San Diego County COVID-19 database, and by analyzing SARSCoV-2 antibody patterns to
differentiate between natural infection and vaccine-induced immunity. Results will be used to estimate
effect sizes for a future efficacy trial and shared with the RADxUP consortium, policymakers and
program planners. Since there are 185 SSPs across the country, our study will inform efforts to enable
SSPs to become important ‘touchpoints’ to reach marginalized PWID, strengthening the nation’s
pandemic preparedness infrastructure to reduce COVID-19 health disparities.
这一竞争性修订旨在增加COVID-19检测和疫苗接种的可及性和使用率
在注射毒品者(PWID)中,这是一个极易感染COVID-19的人群。拟议
RADxUP项目,LinkUP,将嵌套在我们的母基金,洛杉矶圣地亚哥组成部分
Frontera,由NIDA于04/20资助。到目前为止,31%的拉弗龙特拉PWID已经测试了SARS-
CoV-2抗体+,其中65%此前未接受过COVID-19检测。只有3%的人
到2021年5月接种疫苗,45%的人对疫苗犹豫不决。我们的具体目标是:目标1。前瞻性
评估PWID中COVID-19检测的患病率、预测因素和障碍。AIM 2.到
前瞻性评估PWID中COVID-19疫苗接种的发病率、预测因素和障碍。AIM 3.
调整和试行移动的注射器服务项目(SSP)提供的干预措施,
在残疾人中开展COVID-19检测和疫苗接种。AIM 4.为了比较COVID检测和
国家引入a)COVID-19快速检测和B)COVID-19之前和之后的疫苗接种率
在SSP接种疫苗,这是一个自然的实验。AIM 5.前瞻性评估
COVID-19检测和疫苗接种对PWID行为的影响。为了实现目标1和2,我们将
在拉弗龙特拉对400名PWID进行采访,结果将于2021年秋季公布。基于
这些调查结果和我们的社区和科学咨询委员会(CSAB)的投入,我们将选择和
调整简短干预措施,以改善PWID中的COVID-19检测和疫苗接种率
我们的社区合作伙伴OnPoint的移动的货车。LinkUP干预措施随后将在
150名La Frontera PWID的亚组,他们没有接受COVID-19疫苗或检测,
由OnPoint同伴辅导员实施,他们还将提供现场快速COVID-19抗原检测
以及确认性PCR和转诊至最近的COVID-19疫苗接种中心(直至提供疫苗
在国家)。我们将通过正在进行的La
Frontera研究访视,包括自我报告的访谈数据,电子健康记录的链接
圣地亚哥县COVID-19数据库,并通过分析SARSCoV-2抗体模式,
区分自然感染和疫苗诱导的免疫。结果将用于估计
未来疗效试验的效应量,并与RADxUP联盟、政策制定者和
节目策划人由于全国有185个SSP,我们的研究将为努力实现
SSP将成为接触边缘化PWID的重要“接触点”,加强国家的
大流行准备基础设施,以减少COVID-19健康差距。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
STEFFANIE A. STRATHDEE其他文献
STEFFANIE A. STRATHDEE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('STEFFANIE A. STRATHDEE', 18)}}的其他基金
Ethno-epidemiology of HCV, HIV and Overdose associated with Drug Markets and Drug Tourism
与毒品市场和毒品旅游相关的丙型肝炎病毒、艾滋病毒和药物过量的民族流行病学
- 批准号:
10347367 - 财政年份:2020
- 资助金额:
$ 56.18万 - 项目类别:
Ethno-epidemiology of HCV, HIV and Overdose associated with Drug Markets and Drug Tourism
与毒品市场和毒品旅游相关的丙型肝炎病毒、艾滋病毒和药物过量的民族流行病学
- 批准号:
10619365 - 财政年份:2020
- 资助金额:
$ 56.18万 - 项目类别:
Ethno-epidemiology of HCV, HIV and Overdose associated with Drug Markets and Drug Tourism
与毒品市场和毒品旅游相关的丙型肝炎病毒、艾滋病毒和药物过量的民族流行病学
- 批准号:
10754696 - 财政年份:2020
- 资助金额:
$ 56.18万 - 项目类别:
Ethno-epidemiology of HCV, HIV and Overdose associated with Drug Markets and Drug Tourism
与毒品市场和毒品旅游相关的丙型肝炎病毒、艾滋病毒和药物过量的民族流行病学
- 批准号:
10330754 - 财政年份:2020
- 资助金额:
$ 56.18万 - 项目类别:
Ethno-epidemiology of HCV, HIV and Overdose associated with Drug Markets and Drug Tourism
与毒品市场和毒品旅游相关的丙型肝炎病毒、艾滋病毒和药物过量的民族流行病学
- 批准号:
10704856 - 财政年份:2020
- 资助金额:
$ 56.18万 - 项目类别:
Ethno-epidemiology of HCV, HIV and Overdose associated with Drug Markets and Drug Tourism
与毒品市场和毒品旅游相关的丙型肝炎病毒、艾滋病毒和药物过量的民族流行病学
- 批准号:
10559512 - 财政年份:2020
- 资助金额:
$ 56.18万 - 项目类别:
Ethno-epidemiology of HCV, HIV and Overdose associated with Drug Markets and Drug Tourism
与毒品市场和毒品旅游相关的丙型肝炎病毒、艾滋病毒和药物过量的民族流行病学
- 批准号:
10557424 - 财政年份:2020
- 资助金额:
$ 56.18万 - 项目类别:
Ethno-epidemiology of HCV, HIV and Overdose associated with Drug Markets and Drug Tourism
与毒品市场和毒品旅游相关的丙型肝炎病毒、艾滋病毒和药物过量的民族流行病学
- 批准号:
10833944 - 财政年份:2020
- 资助金额:
$ 56.18万 - 项目类别:
Epidemiologic Studies of HMPXV Infection among PWID in the US-Mexico Border Region to Inform Prevention Responses
美墨边境地区吸毒者 HMPXV 感染的流行病学研究,为预防措施提供信息
- 批准号:
10674322 - 财政年份:2020
- 资助金额:
$ 56.18万 - 项目类别:
Ethno-epidemiology of HCV, HIV and Overdose associated with Drug Markets and Drug Tourism
与毒品市场和毒品旅游相关的丙型肝炎病毒、艾滋病毒和药物过量的民族流行病学
- 批准号:
9927215 - 财政年份:2020
- 资助金额:
$ 56.18万 - 项目类别:
相似海外基金
University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
- 批准号:
10073243 - 财政年份:2024
- 资助金额:
$ 56.18万 - 项目类别:
Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
- 批准号:
10752129 - 财政年份:2024
- 资助金额:
$ 56.18万 - 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
- 批准号:
2339201 - 财政年份:2024
- 资助金额:
$ 56.18万 - 项目类别:
Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
- 批准号:
MR/Y008693/1 - 财政年份:2024
- 资助金额:
$ 56.18万 - 项目类别:
Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
- 批准号:
10076445 - 财政年份:2023
- 资助金额:
$ 56.18万 - 项目类别:
Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
- 批准号:
23K14783 - 财政年份:2023
- 资助金额:
$ 56.18万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
- 批准号:
23KJ0394 - 财政年份:2023
- 资助金额:
$ 56.18万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
- 批准号:
10639161 - 财政年份:2023
- 资助金额:
$ 56.18万 - 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
- 批准号:
10752441 - 财政年份:2023
- 资助金额:
$ 56.18万 - 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
- 批准号:
10867639 - 财政年份:2023
- 资助金额:
$ 56.18万 - 项目类别: